Biogen Idec (NQ:BIIB)

218.42 -1.46 (-0.66%)

Delayed Quote Updated: 11:24 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

62 63 Next >

Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals ↗

July 28, 2023

Reata stock surged more than 50% on the news.

Via Investor's Business Daily

Biogen Bolsters Rare Disease Portfolio, Agrees To Buy Reata Pharmaceuticals With Enterprise Value Of $7.3B ↗

July 28, 2023

Biogen Inc (NASDAQ: BIIB) has agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of

Via Benzinga

Biogen to Acquire Reata Pharmaceuticals

July 28, 2023

From Biogen Inc.

Via GlobeNewswire

Neuroinflammation A Key Indicator For Alzheimer’s, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?

July 27, 2023

--News Direct--

Via News Direct

I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO ↗

July 27, 2023

Biogen shares have stagnated in recent years, but the company has a plan to change that.

Via The Motley Fool

Analyst Ratings for Biogen ↗

July 26, 2023

Via Benzinga

Biogen (BIIB) Q2 2023 Earnings Call Transcript ↗

July 25, 2023

BIIB earnings call for the period ending June 30, 2023.

Via The Motley Fool

Biogen Inc. Tops Q2 Earnings And Revenue Estimates ↗

July 25, 2023

Biogen Inc. came out with quarterly earnings of $4.02 per share.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023 ↗

July 27, 2023

Via Benzinga

Why Sage Therapeutics Stock Is Tumbling Today ↗

July 26, 2023

A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today.

Via The Motley Fool

Why Biogen Stock Got Sick Today ↗

July 25, 2023

While the company has won approval for a promising drug, it's cutting costs in the wake of that regulatory green light.

Via The Motley Fool

Better Big Biotech Buy: Vertex vs. Biogen ↗

July 24, 2023

These companies have a track record of billion-dollar earnings.

Via The Motley Fool

Biogen Earnings Preview ↗

July 24, 2023

Via Benzinga

Biogen Unusual Options Activity ↗

July 21, 2023

Via Benzinga

(BIIB) - Analyzing Biogen's Short Interest ↗

July 20, 2023

Via Benzinga

Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event, TikTok Takes On Twitter, Analysts Expect Nvidia's AI Revenues To Reach $300B In Five Years: Today's Top Stories ↗

July 25, 2023

The Hill Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event

Via Benzinga

WMT Stock Alert: Is Walmart Really Worth $210? ↗

July 25, 2023

Walmart (WMT) stock is in the news Tuesday as investors react to the latest coverage from Piper Sandler analyst Edward Yruma.

Via InvestorPlace

MBLY Stock Alert: Morgan Stanley Restarts Mobileye Coverage ↗

July 25, 2023

Mobileye (MBLY) stock is on the move Tuesday after Morgan Stanley analyst Adam Jonas renewed coverage of the company's shares.

Via InvestorPlace

Biogen Layoffs 2023: What to Know About the Latest BIIB Job Cuts ↗

July 25, 2023

Biogen (BIIB) layoffs are on the way as the company seeks further profits with its upcoming Alzheimer's disease drug launch.

Via InvestorPlace

Is Biogen Stock a Buy Now? ↗

July 19, 2023

The biotech hasn't been the best investment recently.

Via The Motley Fool

Should You Buy the Dip With Biogen Stock Right Now? ↗

July 17, 2023

It's expected to grow, but things might not work out precisely as planned.

Via The Motley Fool

Biogen Q2 Earnings Tops Expectations, Shift Resources To Higher Value Area(s), Layoff 1K Staff ↗

July 25, 2023

Biogen Inc (NASDAQ: BIIB) posted Q2 FY23 sales of $2.46 billion, beating the con

Via Benzinga

Nasdaq Futures Rise Ahead Of Microsoft, Alphabet Earnings: Analyst Warns Of Volatility From Fed's Message 'Crafting' ↗

July 25, 2023

Via Benzinga

All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings ↗

July 24, 2023

Analysts expect Biogen to report a a decline in both profits and sales in Q2.

Via Investor's Business Daily

Goldman Sachs, Charles Schwab And This Healthcare Stock On CNBC's 'Final Trades' ↗

July 21, 2023

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Biogen Inc.

Via Benzinga

Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023

July 19, 2023

From Biogen Inc.

Via GlobeNewswire

Acumen Soars on Alzheimer's Study...Street Sees It Doubling

July 19, 2023

Will the $11.00 level be a double-top ceiling…or can Acumen Pharmaceuticals build momentum and climb towards its $25.00 IPO price?

Via MarketBeat

Topics Initial Public Offering

These 2 Numbers Should Scare Every Biogen Shareholder ↗

July 16, 2023

There are a couple of pieces of evidence that Biogen's long-term strategy isn't working.

Via The Motley Fool

7 Stocks That AI Says Will Make You a Millionaire by 2025 ↗

July 13, 2023

These seven millionaire-maker stocks are changing hands at deeply undervalued levels. As their growth re-accelerates, so will your portfolio.

Via InvestorPlace

Why Isn't Biogen Stock Soaring After This Major FDA Approval? ↗

July 13, 2023

Is the stock a good contrarian buy?

Via The Motley Fool

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

62 63 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.